Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (14897)	2/12/1998 4:20:00 PM
From: Machaon	Read Replies (2) \| Respond to of 32384

<< ... heard from a couple of sources that rodent models for human cancer are not highly predictive of human results. >> The Tamoxifen rat test was performed in Dec, 1996. It eventually led to a commercial product. Targretin's 72% tumor regression rate is outstanding. Perhaps this "rat" controversy is what is keeping LGND from exploding upwards, at this time. I wonder why so many rats are used in testing, if the results are so suspect!? Everytime LGND publishes another success story, it makes me feel a little more secure about my investment in LGND. It reinforces my confidence in their science. Regards, and good luck, Bob